ClinicalTrials.Veeva

Menu

The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric

A

Air Force Military Medical University of People's Liberation Army

Status

Enrolling

Conditions

Precancerous Lesion of Digestive Tract
Gastric Cancer
Extrachromosomal DNA

Treatments

Procedure: gastroscopy

Study type

Observational

Funder types

Other

Identifiers

NCT05956847
Gang Ji -3

Details and patient eligibility

About

ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our understanding of tumor formation and evolution. The changes in ecDNA expression in intestinal type gastric cancer may be closely related to the occurrence and development of gastric cancer. Dynamic monitoring of changes in ecDNA expression in the gastric mucosa may help predict the occurrence of gastric cancer and guide subsequent treatment. By collaborating with multiple endoscopic centers to conduct gastroscopy biopsies on patients with gastric precancerous lesions, we aim to further explore the role of ecDNA in the occurrence and development of gastric cancer through continuous follow-up.

Enrollment

1,000 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Age: 18-80 years old;
  2. Patients who plan to undergo gastroscopy at the endoscopic center and patients who undergo surgical treatment for gastric adenocarcinoma;
  3. Endoscopy doctors believe that pathological biopsy is necessary to clarify the pathological diagnosis;
  4. No serious diseases or other systemic malignancies in terms of physical and mental health;
  5. More than one item of non Atrophic gastritis, Atrophic gastritis, intestinal metaplasia, heterogeneous hyperplasia (low grade intraepithelial neoplasia and high grade intraepithelial neoplasia), and gastric adenocarcinoma;
  6. Sign an informed consent form;

Exclusion Criteria:

  1. Pathological results indicate other malignant tumors of the stomach, such as stromal tumors and lymphoma;
  2. The patient and their family members do not agree to use the specimen for later research projects;
  3. Before gastroscopy or surgery, neoadjuvant therapy or combined with other malignant tumors;
  4. Non R0 resected gastric cancer patients;
  5. Pregnant or lactating women;
  6. Have a history of drug abuse such as alcohol and tobacco.

Trial design

1,000 participants in 1 patient group

Gastric precancerous lesions,Normal gastric mucosal tissue and gastric cancer tissues
Description:
Normal gastric mucosal tissue Gastric precancerous lesions:Atrophic gastritis, non Atrophic gastritis, intestinal metaplasia, dysplasia gastric cancer tissues
Treatment:
Procedure: gastroscopy

Trial contacts and locations

1

Loading...

Central trial contact

wei jiangpeng, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems